OCUL Q2 Loss Narrows as Revenue Tops Estimates at $13.48M
Ocular Therapeutix reports a smaller-than-expected Q2 loss and revenue exceeding forecasts by $0.28M. Ocular Therapeutix posted a Q2 GAAP loss of $0.35 per share, beating expectations by $0.04. Revenue reached $13.48M, surpassing estimates by $0.28M despite a 0.1% year-ove